7bet sign up
2025-01-12   

7bet sign up 。

ANDOVER, Mass. , Dec. 2, 2024 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the appointment of Mr. Gerardo Hernandez as the Company's Chief Financial Officer, effective December 2, 2024 . In this role, Mr. Hernandez joins the TransMedics executive leadership team, succeeding Mr. Stephen Gordon . To enable a smooth transition, Mr. Gordon will remain a non-executive employee of the Company until March 31, 2025 , before serving as a non-employee senior advisor to the Company focusing on national transplant stakeholder engagement until March 31, 2026 . TransMedics also updated its 2024 financial outlook. Dr. Waleed Hassanein , Mr. Gerardo Hernandez and Mr. Stephen Gordon will attend the upcoming Piper Sandler Conference on December 3, 2024 , the TransMedics Investor & Analyst Day on December 10, 2024 , as well as the J.P. Morgan Healthcare Conference in January 2025 . Mr. Hernandez is an accomplished finance leader with over 25 years of experience across the healthcare and consumer packaged goods (CPG) sectors. He most recently served as Vice President Finance, Head of Corporate Financial Planning and Analysis at Alnylam Pharmaceuticals, a biopharmaceutical company focused on RNAi therapeutics. In this role, Mr. Hernandez led a global team as the company scaled rapidly. Prior to his role at Alnylam, Mr. Hernandez spent nearly a decade at Shire, where he rose through the organization, eventually leading corporate FP&A. During his tenure, Shire was acquired by Takeda in a $62 billion transaction, after which he was instrumental in the integration effort. Mr. Hernandez began his career at Unilever where he held several finance roles of increasing responsibility before joining Shire in 2010. Mr. Hernandez holds a Bachelor of Science degree in Finance from the University of Wisconsin , La Crosse and an MBA in Strategy and Economics from Fundação Getulio Vargas , Sao Paulo, Brazil . "Stephen has been an exceptional partner to me as a member of the TransMedics leadership team for nearly a decade. During his tenure we transitioned the Company from a clinical stage organization to a high growth, publicly traded commercial business," said Waleed Hassanein , M.D., President and Chief Executive Officer. "On behalf of the entire management team and the Board, I want to thank Stephen for his countless contributions to our business that will have lasting benefits for the Company. I am grateful for Stephen's dedication and efforts to advance our corporate strategy while delivering considerable shareholder value, and I look forward to his continued partnership to affect a smooth transition as we start our next chapter at TransMedics." "I am delighted to welcome Gerardo to the TransMedics leadership team as our new Chief Financial Officer," added Dr. Hassanein. "His proven record over two decades of leadership across FP&A functions within high-growth, complex global organizations makes him an ideal addition to our team. I am looking forward to partnering with Gerardo as we continue to deliver significant long-term corporate growth and shareholder value." "I am thrilled to join TransMedics as Chief Financial Officer," said Mr. Hernandez. "I look forward to working with the entire leadership team to expand access to the Company's unparalleled products and services in the organ transplant field while enhancing operational efficiency and delivering lasting value to both our shareholders and the patients we serve." Dr. Hassanein concluded, "As we enter the final weeks of the fourth quarter, we are also updating our financial outlook for the full year 2024. Our updated guidance reflects our continued expectation for considerable year-over-year revenue growth. We look forward to providing additional context at our upcoming Investor & Analyst Day." 2024 Financial Outlook TransMedics now expects revenue for the full year 2024 to be in the range of $428 million to $432 million, which represents 77% to 79% growth compared to the Company's prior year revenue. Piper Sandler 36th Annual Healthcare Conference Members of the TransMedics management team will participate in a fireside chat at the upcoming Piper Sandler 36th Annual Healthcare Conference at the Lotte New York Palace. The fireside chat will take place on Tuesday, December 3, 2024 , at 4:00 p.m. Eastern Time . A live and archived webcast of the fireside chat will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . The Company's standard investor presentation is also available through this link. TransMedics Investor & Analyst Day Details TransMedics will discuss the transition and updated financial outlook, as well as the Company's growth strategy, clinical pipeline, and operations, in greater detail at its Investor & Analyst Day in New York City on Tuesday, December 10, 2024 , at 10:00 a.m. Eastern Time . A live and archived webcast of presentations and Q&A sessions will be available on the "Investors" section of the TransMedics website at https://investors.transmedics.com . Please note management will only take questions from the live audience during the question-and-answer session following formal presentations. About TransMedics Group, Inc. TransMedics is the world's leader in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Headquartered in Andover, Massachusetts , the company was founded to address the unmet need for more and better organs for transplantation and has developed technologies to preserve organ quality, assess organ viability prior to transplant, and potentially increase the utilization of donor organs for the treatment of end-stage heart, lung, and liver failure. Forward-Looking Statements This press release contains forward-looking statements with respect to, among other things, a leadership transition and our full-year guidance. For this purpose, all statements other than statements of historical facts are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "could," "target," "predict," "seek" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are subject to a number of risks and uncertainties. Our management cannot predict all risks, nor can we assess the impact of all factors or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in or implied by any forward-looking statements we may make. In light of these risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated in or implied by the forward-looking statements. Some of the key factors that could cause actual results to differ include: our ability to maintain profitability on a sustained basis; our ability to attract, train and retain key personnel; our existing and any future indebtedness, including our ability to comply with affirmative and negative covenants under our credit agreement to which we will remain subject until maturity; the fluctuation of our financial results from quarter to quarter; our need to raise additional funding and our ability to obtain it on favorable terms, or at all; our ability to use net operating losses and research and development credit carryforwards; our dependence on the success of the Organ Care System or OCS; our ability to expand access to the OCS through our National OCS Program or NOP; our ability to scale our manufacturing and sterilization capabilities to meet increasing demand for our products; the rate and degree of market acceptance of the OCS; our ability to educate patients, surgeons, transplant centers and private and public payors on the benefits offered by the OCS; our ability to improve the OCS platform and develop the next generation of the OCS products; our dependence on a limited number of customers for a significant portion of our revenue; our ability to maintain regulatory approvals or clearances for our OCS products in the United States , the European Union, and other select jurisdictions worldwide; our ability to adequately respond to the Food and Drug Administration or FDA, or other competent authorities, follow-up inquiries in a timely manner; the performance of our third-party suppliers and manufacturers; our use of third parties to transport donor organs and medical personnel for our NOP and our ability to maintain and grow our logistics capabilities to support our NOP and reduce dependence on third party transportation, including by means of attracting, training and retaining pilots, and the acquisition, maintenance or replacement of fixed-wing aircraft for our aviation transportation services or other acquisitions, joint ventures or strategic investments; our ability to maintain Federal Aviation Administration or FAA or other regulatory licenses or approvals for our aircraft transportation services; price increases of the components of our products and maintenance, parts and fuel for our aircraft; the timing or results of post-approval studies and any clinical trials for the OCS; our manufacturing, sales, marketing and clinical support capabilities and strategy; attacks against our information technology infrastructure; the economic, political and other risks associated with our foreign operations; our ability to protect, defend, maintain and enforce our intellectual property rights relating to the OCS and avoid allegations that our products infringe, misappropriate or otherwise violate the intellectual property rights of third parties; the pricing of the OCS, as well as the reimbursement coverage for the OCS in the United States and internationally; regulatory developments in the United States, European Union and other jurisdictions; the extent and success of competing products or procedures that are or may become available; our ability to service our 1.50% convertible senior notes, due 2028; the impact of any product recalls or improper use of our products; our estimates regarding revenues, expenses and needs for additional financing; and other factors that may be described in our filings with the Securities and Exchange Commission (the "SEC"). Additional information will be made available in our annual and quarterly reports and other filings that we make with the SEC. The forward-looking statements in this press release speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and we are not able to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law. Investor Contact: Brian Johnston Laine Morgan 332-895-3222 Investors@transmedics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/transmedics-appoints-gerardo-hernandez-as-chief-financial-officer-and-provides-updated-2024-financial-outlook-302320060.html SOURCE TransMedics Group, Inc.What Dabo Swinney said after Clemson’s rivalry game loss to South Carolina

Minnesota Tech Industry Thrives with Booming Job Market and University Support, Notes U of M Faculty DirectorPioneer Bancorp stock hits 52-week high at $11.9 amid growth

Rio Tinto-backed lithium tech startup set to raise second round of funds

-- Reduces total emissions by approximately 14 percent since base year -- -- Decreases water withdrawal by approximately 17 percent since base year -- -- Achieves lost-time injury rate of 0.28, representing an approximate 32 percent reduction from prior year -- MORRISVILLE, N.C. , Dec. 11, 2024 /PRNewswire/ -- Pyxus International, Inc. (OTC Pink: PYYX), a global value-added agricultural company, today published its Fiscal Year 2024 Sustainability Report detailing the measurable impacts of the Company's sustainability initiatives as it progresses toward achieving its global targets. "Fiscal year 2024 was an exceptional year for Pyxus and this report highlights the positive impacts of our environmental and social initiatives, including collaboration with our contracted growers to reduce scope 3 emissions, improvement of our employee health and safety practices, and providing support to those in need," said Pyxus President and CEO Pieter Sikkel . "We remain committed to viewing all aspects of our business through a sustainable lens, helping us progress against our targets while delivering value to our stakeholders, the environment and the communities in which we operate." Notable fiscal year 2024 sustainability achievements include: Minimal Environmental Impact Support for People and Communities Ethical and Responsible Business In preparation of this year's report, Pyxus externally verified 11 global key performance indicators (KPIs) associated with its targets, up from three KPIs in the prior year. The report was prepared with reference to Global Reporting Initiative (GRI) Standards, aligns with the United Nations Sustainable Development Goals and discloses the Company's sustainability performance from April 1, 2023 , to March 31, 2024 . About Pyxus International, Inc. Pyxus International, Inc. is a global agricultural company with more than 150 years of experience delivering value-added products and services to businesses and customers. Driven by a united purpose—to transform people's lives, so that together we can grow a better world—Pyxus International, its subsidiaries and affiliates, are trusted providers of responsibly sourced, independently verified, sustainable, and traceable products and ingredients. For more information, visit www.pyxus.com . View original content to download multimedia: https://www.prnewswire.com/news-releases/pyxus-releases-fiscal-year-2024-sustainability-report-302329534.html SOURCE Pyxus International, Inc.

The Washington Commanders released 2023 first-rounder Emmanuel Forbes on Saturday, cutting ties with another high draft pick from the previous regime. All of previous coach Ron Rivera's first-rounders — including edge rusher Chase Young in 2020, linebacker Jamin Davis in ‘21 and wide receiver Jahan Dotson in '22 — are now gone. Forbes never showed progress to the new staff led by coach Dan Quinn and was a healthy scratch twice this season and did not play in two other games during which the 23-year-old was in uniform. Javascript is required for you to be able to read premium content. Please enable it in your browser settings. Get updates and player profiles ahead of Friday's high school games, plus a recap Saturday with stories, photos, video Frequency: Seasonal Twice a week

Almost one year into her reign, it looks like Australian-born Queen Mary of Denmark may be ascending to a prestigious new role: podcast host. The Danish queen announced this week that her charity, the Mary Foundation, is launching a podcast called Lonely Youth. The three-part series inspired by Denmark’s high rates of youth loneliness promises to “give an in-depth insight into the nuances of loneliness by mixing [expert analysis] and personal narratives from young people”. Though we don’t yet know if she will feature in each episode, Queen Mary announced the news via Instagram, pointing out that a recent study found 73 per cent of Danes, aged 16-19, experience loneliness and 17 per cent of those, between 16-24, feel “very lonely”. “These are heavy numbers that we need to do something about,” the post read. At first glance, it might seem strange that a 52-year-old monarch would be the go-to person to reach disconnected youth – and stranger still that they would do so via a medium often associated with influencers, true-crime detectives and young men in basements. But, this is actually the latest in a long line of royal podcasting projects (and no, it didn’t start with Meghan Markle). The rise of royal podcasting Dr Lisa Beckett, a lecturer at the University of New England researching royalty and popular culture, says it was only a matter of time before royal family members entered the podcast market. “Royals tend to be later than everybody else entering these spaces,” she says, “but [engaging in new mediums] is one of the ways they stay relevant.” And, as a kind of celebrity (“they have been since the time of the Georgians”, she notes), this kind of direct contact with audiences is expected of them. “Queen Elizabeth could get away with quite a bit of distance because she started her reign so long ago, but the younger royals are expected to act more modern and to be in this space ... That distance between celebrities and fans has been shrinking, particularly with social media.” India Hicks, goddaughter of King Charles, was the first notable name to get in on the action. The India Hicks Podcast , which debuted in 2019, offered a “wonderfully intimate look” into her life and her “extraordinary family”. It consisted of conversations about “movie stars, matadors and maharajas” with her mother, Lady Pamela Hicks, the late Queen Elizabeth’s former lady-in-waiting. A couple of years later, Princess Eugenie co-hosted Floodlight : an interview podcast about modern slavery made with her charity, the Anti-Slavery Collective. Then came Meghan Markle’s Archetypes. In this much-hyped 2022 series, the Duchess of Sussex spoke to some of the biggest names in popular culture (including Mariah Carey, Paris Hilton and Serena Williams) about the “labels that try to hold women back”. The following year Sarah “Fergie” Ferguson, the Duchess of York, debuted a chat podcast with her friend Sarah Thomson, and Queen Camilla launched The Queen’s Reading Room podcast. The latter, an extension of her literacy charity of the same name, features interviews with authors and prominent book-lovers such as Dame Joanna Lumley and Richard E. Grant. But Camilla is only featured for a couple of minutes per episode. Though podcasts are an intimate medium, as Dr Beckett points out, they also enable royals to maintain a great deal of control – certainly more so than in a traditional TV interview. “They have to be careful because they’ve tried different tactics like this,” Beckett says. “In 1969, Queen Elizabeth actually allowed for a documentary of her home life. It was broadcast on the BBC once, then she realised it was a mistake. It let people in too much into her personal life, and she actually banned it from being ever played again.” (Decades later, it leaked on YouTube .) In 1987, younger members of the British royal family also competed in the TV game show It’s a Royal Knockout alongside celebrities, running around in costumes doing obstacle courses for charity. “People thought it was a disaster,” Beckett says. “Royals are not like other celebrities, they have to act a certain way and maintain certain standards ... but at the same time be ‘normal enough’ that we [relate to] them.” Moral influencers or ‘f---ing grifters’? So, do people actually care about this exclusive royal content or are they content just watching The Crown ? The most successful of the bunch is undoubtedly Meghan Markle’s Archetypes. The show debuted in the top spot on Spotify in Britain, the US, Canada, Ireland, India, Australia and New Zealand. But it also lost a lot of steam by the end of the season, and Meghan and Harry’s Archewell Audio “mutually agreed” to leave Spotify soon after. Meghan Markle made one season of Archetypes , in collaboration with Spotify. Credit: Their initial deal reportedly cost $US25 million ($38.5 million), and The Wall Street Journal reported the couple had failed to meet “productivity benchmarks” to justify the sum. Though their 2020 agreement promised “a multi-year partnership ... to produce podcasts and shows” (multiple), nothing else materialised. Bloomberg reported that Harry had pitched a number of ideas, including a show in which he interviewed “controversial guests such as Vladimir Putin, Mark Zuckerberg and Donald Trump about their early formative years”. Celebrating their exit from the company, Spotify executive Bill Simmons went so far to call the pair “f---ing grifters” on his own podcast. He had also previously criticised Prince Harry, saying: “Why are we listening to you? Nobody cares what you have to say about anything unless you talk about the royal family, and you just complain about them.” Dr Beckett believes it is a good thing, however, when royals publicly lend themselves to causes. Whether it’s Princess Eugenie with modern slavery or Queen Mary with youth loneliness – or, historically, Princess Diana with AIDS – “royalty adds cachet”. “When they get involved, it really gives the charity or the cause a lot of support and a lot of attention,” she says. At the very least, she adds, “It gets the attention of the media.” Find out the next TV, streaming series and movies to add to your must-sees. Get The Watchlist delivered every Thursday .

CardioFocus Announces First Patients Treated with OptiShotTM Pulsed Field Ablation System

Related hot word search:

Previous: 7bet kazino
Next: 8 0 8 meaning